Immutep Financials - Benzinga

Immutep Ltd

IMMPNASDAQ

Trade with Public

Trade with Public

$0.3800

-0.0235-5.82%

At close: Aug 14, 5:00 PM EST

$0.3805

0.00050.13%

After Hours: Aug 14, 7:02 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Immutep Financials

Immutep (IMMP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September

Avi Kapoor

Immutep Up as Combo Therapy Meets Carcinoma Study Goals

Immutep Limited (NASDAQ: IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) study.

Zacks

Immutep Reported Cash, Cash Equivalent Balance Of $95.4M As Of March 31, 2024, Giving It Expected Cash Reach Into Early CY2026

Charles Gross

PRO
Immutep Q2 2024 Cash And Cash Equivalent ~103.7M

Benzinga Newsdesk

PRO
Immutep Quarterly Activities Report Q1 FY24; With A Cash And Cash Equivalent Balance As At 30 September 2023 Of Approximately $110.1M

FINANCIAL SUMMARYImmutep continued to prudently manage its cashflow over the first quarter of the new financial year (Q1 FY24), while strategically investing into clinical trial programs for efti.With a cash and cash

Benzinga Newsdesk

Immutep's Cash And Cash Equivalent Balance As At 30 June 2023 Was ~$123.4M

Happy Mohamed